UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 131

Sortiert nach

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-09, Vol.13 (5), p.451-461

2007

Volltextzugriff (PDF)

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.691-697

2013

Volltextzugriff (PDF)

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.698-705

2013

Volltextzugriff (PDF)

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-11, Vol.23 (6), p.821-831

2017

Volltextzugriff (PDF)

Recombinant activated factor VII in approved indications: Update on safety

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e275-e277

2018

Volltextzugriff (PDF)

Re: Discordant pair analysis of rFVIIa and pd-aPCC response

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-03, Vol.17 (2), p.323-325

2011

Volltextzugriff (PDF)

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal

Journal of thrombosis and haemostasis, 2005-04, Vol.3 (4), p.820-822

2005

Volltextzugriff (PDF)

Modern treatment of haemophilia

Bulletin of the World Health Organization, 1995-01, Vol.73 (5), p.691-701

1995

Volltextzugriff (PDF)

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 1999-01, Vol.5 (1), p.9-16

1999

Volltextzugriff (PDF)

Cost minimization model for treatment of minor bleeding episodes in inhibitor patients - methodological issues

Haemophilia : the official journal of the World Federation of Hemophilia, 2006-01, Vol.12 (1), p.108-109

2006

Volltextzugriff (PDF)

Internalization of Human Immunodeficiency Virus Type I and Other Retroviruses by Megakaryocytes and Platelets

Blood, 1990-05, Vol.75 (10), p.1920-1923

1990

Volltextzugriff (PDF)

Growth- and Tumor-Promoting Effects of Deregulated BCL2 in Human B-Lymphoblastoid Cells

Proceedings of the National Academy of Sciences - PNAS, 1989-06, Vol.86 (12), p.4589-4593

1989

Volltextzugriff (PDF)

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Journal of thrombosis and haemostasis, 2009-03, Vol.7 (3), p.413-420

2009

Volltextzugriff (PDF)

Desmopressin nasal spray for hemophilia A and type I von Willebrand disease

Annals of internal medicine, 1997-05, Vol.126 (9), p.744

1997

Volltextzugriff (PDF)

Biochemistry and expression of myelomonocytic antigens

The Journal of immunology (1950), 1986-12, Vol.137 (12), p.3909

1986

Volltextzugriff (PDF)

Monoclate-P--hemofil-M study

Annals of hematology, 1994-01, Vol.68 Suppl 3 (S3), p.S45-S47

Seremetis, S

1994

Volltextzugriff (PDF)

The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients

Seminars in hematology, 1994-04, Vol.31 (2 Suppl 4), p.53

Seremetis, S V

1994

Volltextzugriff (PDF)

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Blood coagulation & fibrinolysis, 2003-06, Vol.14 Suppl 1 (SUPPLEMENT 1), p.S29-S30

Seremetis, Stephanie

2003

Volltextzugriff (PDF)

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate

The Lancet (British edition), 1994-09, Vol.344 (8925), p.791-792

1994

Volltextzugriff (PDF)

Sex-related differences in hemostasis and thrombosis

The journal of gender-specific medicine, 2001, Vol.4 (2), p.59

Seremetis, S V

2001

Volltextzugriff (PDF)

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status

The Lancet (British edition), 1993-09, Vol.342 (8873), p.700-703

1993

Volltextzugriff (PDF)

Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice

Child abuse & neglect, 2003-11, Vol.27 (11), p.1247-1258

2003

Volltextzugriff (PDF)

Re: Discordant pair analysis of rFVIIa and pd-aPCC response: LETTERS TO THE EDITORS

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-03, Vol.17 (2), p.323-325

2011

Volltextzugriff (PDF)

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

Journal of thrombosis and haemostasis, 2010-04, Vol.8 (4), p.730-736

2010

Volltextzugriff (PDF)

High frequency of clonal immunoglobulin or T cell receptor gene rearrangements in acute myelogenous leukemia expressing terminal deoxyribonucleotidyltransferase

The Journal of experimental medicine, 1987-06, Vol.165 (6), p.1703-1712

1987

Volltextzugriff (PDF)

1 – 25 von 131

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(82)
Science & Technology
(64)
Life Sciences & Biomedicine
(60)
Biological And Medical Sciences
(35)
Hematology
(32)
Male
(30)
Medical Sciences
(30)
Adult
(28)
Middle Aged
(25)
Female
(22)
Hemophilia A - Drug Therapy
(20)
Adolescent
(16)
Aged
(16)
Child
(16)
Hematologic And Hematopoietic Diseases
(14)
Cardiovascular System & Cardiology
(12)
Peripheral Vascular Disease
(10)
Recombinant Proteins - Administration & Dosage
(10)
Recombinant Proteins - Therapeutic Use
(10)
Animals
(9)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices

Recombinant activated factor VII in approved indications: Update on safety

Re: Discordant pair analysis of rFVIIa and pd-aPCC response

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal

Modern treatment of haemophilia

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy

Cost minimization model for treatment of minor bleeding episodes in inhibitor patients - methodological issues

Internalization of Human Immunodeficiency Virus Type I and Other Retroviruses by Megakaryocytes and Platelets

Growth- and Tumor-Promoting Effects of Deregulated BCL2 in Human B-Lymphoblastoid Cells

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Desmopressin nasal spray for hemophilia A and type I von Willebrand disease

Biochemistry and expression of myelomonocytic antigens

Monoclate-P--hemofil-M study

The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients

Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate

Sex-related differences in hemostasis and thrombosis

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status

Childhood emotional abuse and neglect as predictors of psychological and physical symptoms in women presenting to a primary care practice

Re: Discordant pair analysis of rFVIIa and pd-aPCC response: LETTERS TO THE EDITORS

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

High frequency of clonal immunoglobulin or T cell receptor gene rearrangements in acute myelogenous leukemia expressing terminal deoxyribonucleotidyltransferase

Suchergebnisse filtern